2+ hour, 45+ min ago  (256+ words) Conexiant The US Food and Drug Administration approved gedatolisib (Revtorpyk) for use with fulvestrant, with or without palbociclib, in adults with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer lacking a detected PIK3CA mutation following…...

2+ week, 4+ day ago  (41+ words) Conexiant ESMO Breast Cancer 2026 Highlights: TRAK-ER Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH discuss results from the TRAK-ER trial, which were presented at the 2026 ESMO Breast Cancer Congress....

2+ week, 4+ day ago  (51+ words) Conexiant ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325 Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Pumitamig + DB-1305/BNT325 trial, which were presented at the 2026 ESMO Breast Cancer Congress....

2+ week, 4+ day ago  (50+ words) Conexiant ESMO Breast Cancer 2026 Highlights Panel Discussion Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Erica L. Mayer, MD, MPH; Nancy Lin, MD; and Ana C. Garrido-Castro, MD discuss important breast cancer research presented at the 2026 ESMO Breast Cancer Congress....

2+ mon, 2+ week ago  (167+ words) Infants who received nirsevimab may have a lower risk of hospitalization for respiratory syncytial virus compared with those whose mothers received a vaccine during pregnancy, according to a nationwide study. This study represented one of the first large, real-world comparisons…...

3+ mon, 2+ week ago  (166+ words) MRI study finds stronger associations than estradiol across menstrual phases Fluctuations in sex hormones across the menstrual cycle may influence brain structure, with progesterone showing stronger and more consistent associations than estradiol, according to a study published in eBioMedicine. In…...

3+ mon, 4+ week ago  (48+ words) Conexiant SABCS 2025 Highlights: Hormone Replacement Therapy for Breast Cancer Harold Burstein, MD, PhD, and Wendy Y. Chen, MD, MPH, discuss research in hormone replacement therapy for breast cancer that was presented at the 2025 San Antonio Breast Cancer Symposium....